CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Individual Patient Compassionate Use of Fedratinib

Conditions: Myelofibrosis

First Posted Date: 2018-10-29

Last Posted Date: 2020-09-18

Lead Sponsor: Celgene

Registration Number: NCT03723148

Locations: 🇺🇸
Celgene, Summit, New Jersey, United States

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: enasidenib
Drug: Arm 2 Probes
Drug: Arm 1 probes
Drug: Arm 3 probes

First Posted Date: 2018-10-25

Last Posted Date: 2024-02-28

Lead Sponsor: Celgene

Target Recruit Count: 40

Registration Number: NCT03720366

Locations: 🇰🇷
Local Institution - 201, Seoul, Korea, Republic of
🇦🇺
Local Institution - 101, Melbourne, Australia
🇰🇷
Local Institution - 203, Seoul, Korea, Republic of

and more 7 locations

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Lymphoma, T-Cell

Interventions: Drug: Romidepsin
Drug: Azacitidine
Drug: Gemcitabine

First Posted Date: 2018-10-12

Last Posted Date: 2024-07-08

Lead Sponsor: Celgene

Target Recruit Count: 93

Registration Number: NCT03703375

Locations: 🇯🇵
Local Institution - 41422, Hidaka, Saitama-Pref, Japan
🇯🇵
Local Institution - 41222, Sendai, Japan
🇯🇵
Local Institution - 41722, Osakasayama, Osaka, Japan

and more 9 locations

Drug-drug Interaction Study of Ozanimod With Tyramine to Evaluate the Effect on Pressor Response

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Phenelzine
Drug: Tyramine
Drug: Phenelzine placebo
Drug: ozanimod
Drug: ozanimod placebo

First Posted Date: 2018-10-03

Last Posted Date: 2019-07-19

Lead Sponsor: Celgene

Target Recruit Count: 92

Registration Number: NCT03694119

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve

Phase 3

Active, not recruiting

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Luspatercept
Drug: Epoetin alfa

First Posted Date: 2018-09-24

Last Posted Date: 2024-11-20

Lead Sponsor: Celgene

Target Recruit Count: 363

Registration Number: NCT03682536

Locations: 🇺🇸
Local Institution - 114, Salt Lake City, Utah, United States
🇺🇸
Local Institution - 107, Berkeley, California, United States
🇺🇸
Local Institution - 115, San Diego, California, United States

and more 223 locations

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ozanimod

First Posted Date: 2018-09-11

Last Posted Date: 2019-02-06

Lead Sponsor: Celgene

Target Recruit Count: 212

Registration Number: NCT03665610

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Biological: bb2121
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Ixazomib
Drug: Lenalidomide
Drug: Carfilzomib
Drug: Elotuzumab

First Posted Date: 2018-08-29

Last Posted Date: 2022-12-15

Lead Sponsor: Celgene

Target Recruit Count: 381

Registration Number: NCT03651128

Locations: 🇺🇸
Local Institution - 145, Los Angeles, California, United States
🇺🇸
Local Institution - 122, Los Angeles, California, United States
🇺🇸
Local Institution - 131, Atlanta, Georgia, United States

and more 57 locations

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Lenalidomide

First Posted Date: 2018-08-27

Last Posted Date: 2025-03-04

Lead Sponsor: Celgene

Target Recruit Count: 105

Registration Number: NCT03647124

Locations: 🇮🇹
Local Institution - 614, Milano, Italy
🇦🇹
Local Institution - 101, Wien, Austria
🇫🇷
Local Institution - 303, Le Chesnay Cedex, France

and more 76 locations

Drug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart Rate

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ozanimod
Drug: ozanimod placebo
Drug: Pseudoephedrine

First Posted Date: 2018-08-23

Last Posted Date: 2019-05-30

Lead Sponsor: Celgene

Target Recruit Count: 54

Registration Number: NCT03644576

Locations: 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States

Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Ozanimod
Drug: Gemfibrozil
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2018-08-10

Last Posted Date: 2019-05-30

Lead Sponsor: Celgene

Target Recruit Count: 100

Registration Number: NCT03624959

Locations: 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy